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Altered histone deacetylase (HDAC) activity has been identified in several types of cancer. This study was designed to determine the
safety and maximum tolerated dose (MTD) of valproic acid (VPA) as an HDAC inhibitor in cancer patients. Twenty-six pre-treated
patients with progressing solid tumours were enrolled in dose-escalating three-patient cohorts, starting at a dose of VPA
30mgkg
 1day
 1. VPA was administered as an 1-h infusion daily for 5 consecutive days in a 21-day cycle. Neurocognitive impairment
dominated the toxicity profile, with grade 3 or 4 neurological side effects occurring in 8 out of 26 patients. No grade 3 or 4
haematological toxicity was observed. The MTD of infusional VPA was 60mgkg
 1day
 1. Biomonitoring of peripheral blood
lymphocytes demonstrated the induction of histone hyperacetylation in the majority of patients and downmodulation of HDAC2.
Pharmacokinetic studies showed increased mean and maximum serum VPA concentrations 4120 and 4250mgl
 1, respectively, in
the 90 and 120mgkg
 1 cohorts, correlating well with the incidence of dose-limiting toxicity (DLT). Neurotoxicity was the main DLT
of infusional VPA, doses up to 60mgkg
 1day
 1 for 5 consecutive days are well tolerated and show detectable biological activity.
Further investigations are warranted to evaluate the effectivity of VPA alone and in combination with other cytotoxic drugs.
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Histone acetylation of nucleosomal histones plays an important
role in gene expression, and consequently affects proper cell
function, differentiation, and proliferation. The acetylation status
of histones is determined by the activity of enzymes called histone
acetyltransferase (HAT) and histone deacetylase (HDAC) (Davie,
1998; Kouzarides, 1999; Strahl and Allis, 2000). Altered HAT and
HDAC activity has been identified in several types of cancer (Cress
and Seto, 2000; Mahlknecht and Hoelzer, 2000; Timmermann et al,
2001), and a number of HDAC inhibitors have been characterised
that inhibit tumour growth in vitro and in vivo (Marks et al,
2000a,b; Takai et al, 2004).
Valproic acid (VPA, 2-propylpentanoic acid) is a well-estab-
lished drug in the long-term therapy of epilepsy and has been
safely used for over three decades. In addition, VPA acts as a
specific inhibitor of class I HDACs and induces proteasomal
degradation of HDAC2, leading to cellular differentiation, growth
arrest, and death in vivo and in vitro (Go ¨ttlicher et al, 2001; Phiel
et al, 2001; Kra ¨mer et al, 2003; Catalano et al, 2005).
Long-term treatment of patients with VPA for prevention of
epileptic seizures is usually performed with doses of 15–
30mgkg
 1day
 1 leading to serum levels of 0.3–0.9mM. With these
doses, the most common adverse effects were transient gastro-
intestinal symptoms, including anorexia, nausea, and vomiting in
about 16% of the patients. Neurotoxic effects, for example,
sedation, ataxia, and tremour occurred less frequently and usually
improved upon dose reduction. Severe VPA-related toxicity has
been reported to involve the liver, pancreas, and haematopoietic
system (Loscher, 1999).
This study was conducted to determine the maximum tolerated
dose (MTD) and toxicity of infusional VPA applicated in two
doses daily in a 5-day schedule. A secondary aim of the study
was the evaluation of the clinical and biological response to VPA
treatment, by monitoring the acetylation status of histones and the
HDAC inhibition in the treated individuals.
PATIENTS AND METHODS
Patient eligibility
Patients with histologically confirmed progressive, advanced stage
malignant disease without any options of standard treatment,
who received at least one prior palliative chemotherapy, were
considered eligible for the study. Further study criteria were
Karnofsky performance status 460, age 418 years, life expectancy
412 weeks, measurable or evaluable disease, no major surgery
within 4 weeks before study entry, and no concurrent anti-cancer
treatment within the last 30 days.
Concurrent uncontrolled medical illness like congestive heart
failure or unstable angina pectoris, previous history of myocardial
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sinfarction within 1 year from study entry, uncontrolled hyperten-
sion or high-risk uncontrolled arrhythmias, history of significant
neurological, psychiatric, or addictive disorders, active peptic
ulcer, unstable diabetes mellitus, active uncontrolled infection,
bleeding disorders, hepatic or pancreatic disease, or severe renal
function impairment were exclusion criteria.
Patients were required to have the following laboratory values,
obtained within 14 days of study participation: granulocytes
42500ml
 1, platelets 4100000ml
 1, haemoglobin 48gdl
 1,
ASAT and ALAT o2.5UNL, a-amylase o130Ul
 1, lipase o300
Ul
 1, and creatinine o2mgdl
 1.
Pregnant or lactating women were excluded and patients of
childbearing potential were required to have negative pregnancy
test and were advised to take adequate precautions to prevent
pregnancy. Participants gave written informed consent before they
entered the study, which was approved by the Local Ethics
Committee.
Trial design and treatment
Patients were enrolled to the study in cohorts of three patients for
each dose level. Projected dose levels were 30, 60, 120, 180, 240,
and 300mgkg
 1 per treatment day. The protocol was amended to
include dose levels 75 and 90mgkg
 1 later.
Patients were planned to receive a total of 20 intravenous
administrations of VPA on days 1–5 and days 22–26. The daily
does of VPA was divided into two equal parts and each part was
given as an intravenous infusion of 60-min duration (VPA was
dissolved in isotonic NaCl 0.9 or 5% glucose solution at a
concentration of 900mg100ml
 1). The first infusion was adminis-
tered in the morning between 0800 and 1000, and the second in the
evening between 2000 and 2200.
Dose escalation to the next dose level was possible, if all patients
of the previous dose levels have reached the end of the first
infusion cycle (treatment days 1–5) without dose-limiting toxicity
(DLT). In case of DLT in one out of three patients, three additional
patients were enrolled to the same dose level. If at least two out of
six patients at the same dose level experienced DLT, this dose level
was closed and the dose level of the previous cohort was defined as
the MTD. No dose adjustments of the study medication were
planned.
Toxicity assessment
All toxicities were graded according to the National Cancer
Institute (NCI) Common Toxicity Criteria (CTC) (version 2).
The following toxicities were considered dose limiting: NCI-CTC
grade 4 anaemia, neutropenia, thrombocytopenia, nausea, vomit-
ing, or any other NCI-CTC grades 3 or 4 non-hematological
toxicities.
Patients receiving at least one dose of VPA were considered
evaluable for toxicity.
Treatment evaluation
The pre-treatment evaluation included a complete history, a
physical examination with a baseline KPS, laboratory studies
(white blood cells and neutrophil count, platelets count, alkaline
phosphatase, ASAT, ALAT, bilirubin, lipase, amylase, and serum
creatinine), imaging studies for tumour measurement/evaluation,
and ECG. During treatment physical examination, laboratory
studies and toxicity assessment were done every day. Tumour
measurement for evaluation of response and ECG were done on
day 40, according to the RECIST criteria.
Patients were considered evaluable for biological and clinical
response after receiving at least 5-day doses of VPA.
Biomonitoring
Blood samples (10ml heparinised peripheral blood and 5ml
serum) were taken before start of the first infusion, and 6h later on
days 1 and 22 for western blot analyses and flow cytometry. Blood
samples were also obtained before the start of the first infusion on
days 3, 5, 24, and 26.
Accumulation of hyperacetylated histones H3, H4, and HDAC2
expression were analysed in cell lysates of peripheral blood
lymphoctes (PBL) by western blotting using antibodies directed
against acetylated histones H3 and H4 (Upstate Biotechnology Inc.,
Lake Placid, NY, USA) and HDAC2 (sc7899, Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA). Whole-cell lysates were
prepared in denaturing SDS sample buffer and separated on 15%
SDS–polyacrylamide gels.
Acetylation status of histone H4 was also analysed in PBL by
flow cytometry with an antibody directed against H4 (T52).
Pharmacokinetics
Blood samples for pharmacokinetic analyses of serum VPA
concentration were taken before the start of first infusion on
every treatment day. Additional samples were obtained on days 4
and 25 immediately after the end of the first infusion (in the
morning) and in some cases, before start of the second infusion (in
the evening).
RESULTS
Patients
Twenty-six patients were enrolled in the study. All patients were
assessable for safety and toxicity analysis. Eighteen patients were
assessable for clinical response. One patient (in the 60mgkg
 1
dose level) discontinued treatment early for reasons other than
toxicity (early tumour progression) and was replaced. The
majority of patients were heavily pre-treated. The patient
characteristics are outlined in Table 1.
Dose escalation
VPA dose levels were escalated from 30mgkg
 1 over 60 to
120mgkg
 1, as planned (at the 30mgkg
 1 dose level, an
additional cohort was opened as one patient had DLT, but
retrospective analysis showed that this adverse event was most
probably related to cerebral metastases and not to VPA). After 42
out of six patients at the 120mgkg
 1 dose level had DLT, the
protocol was amended to include an additional dose level of
90mgkg
 1. A further dose level, 75mgkg
 1, was included per
amendment, as there was DLT in 42 out of six patients at the
90mgkg
 1 dose level. After two out of five patients had DLT at the
75mgkg
 1 dose levels, 60mgkg
 1 was defined as MTD. The dose
escalation schedule is outlined in Table 2.
Fifteen patients received all planned infusions of VPA, and in
nine patients, the treatment was stopped early due to toxicity and
in two patients due to rapid tumour progression. One patient
refused further treatment after the first infusion cycle due to
personal reasons.
Toxicity
The most common type of toxicity in our study was neurological,
occurring in almost all patients in a dose-dependent manner. Eight
patients experienced a DLT. Neurocognitive impairment in form of
confusion or disorientation represented the DLT in seven of these
eight patients.
Five patients had neurovisual or neuroacustical side effects, but
of lower grade. Also grade 1 or 2 vertigo was observed in five out of
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s26 patients. Somnolence occurred in 21 out of 26 patients and was
dose limiting in two patients (both in the 120mg cohort). All
neurological side effects, whether dose limiting or not, resolved
completely after discontinuation of the treatment. The toxicities
are outlined in Table 3.
Haematological and metabolic toxicities were rare and mild
(leucopoenia and thrombocytopenia). Gastrointestinal toxicity was
also of lower grade, with 13 patients suffering from grade 1 or 2
nausea and/or vomiting. No relevant general toxicity was observed,
except that five patients had fatigue, and in two patients, it was of
grade 3 (dose-limiting).
Clinical response
Eighteen (69%) of 26 patients were evaluable for response. No
objective responses were observed. Two patients (one patient
with non-small-cell lung cancer and one additional patient with
colorectal cancer) had stable disease lasting 3 and 5 months,
respectively. Both of the patients were previously treated and had
rapid disease progression under the prior cytotoxic treatment.
Pharmacokinetic studies
At the 30 and 60mgkg
 1 dose levels, the median baseline VPA
concentrations were in the range, normally achieved during
anti-epileptic therapy (50–120mgl
 1; Figure 1A). No DLT was
observed among the patients treated in these dose levels. In
contrast, median VPA concentrations regularly exceeded
120mgl
 1 at the 90 and 120mgkg
 1 dose levels, with a tendency
to higher concentration towards the end of the 5-day treatment
correlating with the incidence of DLTs.
Figure 1B shows the median maximum concentrations of VPA
at different dose levels. At the 30 and 60mgkg
 1 dose levels, the
maximum serum concentration of VPA did not exceed 200mgl
 1,
and at the 90 and 120mgkg
 1 dose levels, median maximum
serum concentrations of VPA were above 200mgl
 1 with
individual concentrations up to 500mgl
 1, indicating that also
the high maximum VPA concentrations may contribute to the
occurrence of DLTs.
Biomonitoring
An increase of histone hyperacetylation was observed in 12 (75%)
out of 16 tested patients under VPA treatment, with either
Table 2 Dose escalation schedule
Cohort
number
Dose (mgkg
 1
body weight)
No. of
patients DLT
1 and 2 30 6 0
a
36 0 3 0
4 and 5 120 5 4
b
6 and 7 90 6 4
8 and 9 75 5 2
DLT, dose-limiting toxicity.
aSymptoms were related to cerebral metastasis.
bOne
additional patient had a delayed adverse event which was later considered DLT
during data monitoring, after the cohort was already extended.
Table 1 Patient characteristics
No. of patients
Patient characteristics (n¼26) %
Age (years)
Median 62.5
Range 39–75
Sex
Female 12 46
Male 14 64
Karnofsky performance status
100 5 19
90 16 62
80 4 15
70 1 4
Tumour type
Colorectal 10 38
Melanoma 4 15
Breast 2 8
Non-small-cell lung cancer 3 12
Prostate 1 4
Ovarian 1 4
Oesophageal 1 4
Ileum 1 4
Thymus 1 4
CUP 1 4
Myeloma 1 4
No of prior palliative chemotherapies
1–2 10 38
3–4 12 46
444 1 5
Organs involved (metastatic)
17 2 7
21 0 3 8
X39 3 5
Table 3 Common toxicity (n¼26 patients)
Grade 1 Grade 2 Grade 3 Grade 4
Toxicity n (%) n (%) n (%) n (%)
Haematological
Leucopenia 3 (12) 1 (4) — —
Thrombocytopenia 2 (8) — — —
Anaemia — — — —
Gastrointestinal
Diarrhoea 2 (8) — — —
Nausea/vomiting 9 (35) 4 (15) — —
Constipation 1 (4) — — —
Anorexia 1 (4) 1 (4) — —
Metabolic
Creatinine — — — —
AST — 1 (4) — —
ALT 1 (4) — — —
Lipase/amylase 1 (4) — — —
Neurological
Neurosensory 4 (15) 1 (4) — —
Neuromotor — — — —
Neurocortical (cognitive
disturbance/confusion)
5 (19) 1 (4) 8 (31) —
Vertigo 4 (25) 1 (4) — —
Neuroconstipation — — 1 (4) —
Headache 2 (8) — — —
Somnolence 15 (58) 4 (15) 2 (8) —
General
Fatigue 1 (4) 2 (8) 2 (8) —
Pain 1 (4) — — —
Fever — — — —
Skin — 1 (4) — —
VPA in advanced cancer
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sH3-hyperacetylation and/or H4-hyperacetylation of PBL, analysed
by Western blot. Figure 2 shows representative results of western
blot analyses in four patients treated at different dose levels.
Histone hyperacetylation did not seem to be dose dependent. Four
patients had no detectable biological activity, two of whom were
treated at 120mgkg
 1, one at 30, and one at 60mgkg
 1 dose level.
Monitoring the histone acetylation of PBMC with T52 via FACS
also showed an increase of the acetylation status of PBL during
VPA treatment in 10 out of 10 patients tested.
The expression of HDAC2 was analysed by western blot in four
patients (at dose levels 30, 60, 90, and 120mgkg
 1). Down-
regulation of HDAC2 was observed in all patients tested (Figure 2).
DISCUSSION
HDAC inhibition represents an interesting mechanism of anti-
cancer treatment. Several HDAC inhibitors, including phenylbu-
tyrate, depsipeptide, and suberoylanilide hydroxamic acid (SAHA)
are currently under investigation in clinical studies (Carducci et al,
2001; Sandor et al, 2002; Kelly et al, 2003, 2005). The compounds
apparently differ in their activity and safety profiles from each
other and from VPA. The fact that VPA has been safely used in the
long-term therapy of patients with epilepsy over decades clearly
represents an advantage of VPA.
Our study was conducted to determine the MTD and define the
DLT of intravenous VPA given as an 1-hour infusion twice daily
for 5 consecutive days in a 21-day cycle in patients with advanced
solid tumours. Furthermore, we conducted a pharmacokinetic
analysis to assess the correlation between the side effects observed
and the VPA serum concentration reached at each dose level. The
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Figure 1 (A) Median VPA concentrations in different dose level cohorts
(30mgkg
 1 (n¼6 patients), 60mgkg
 1 (n¼4 patients), 90mgkg
 1
(n¼6 patients), and 120mgkg
 1 (n¼4 patients)) and (B) median
maximum serum VPA concentrations (cmax) at different dose levels.
30 mg kg−1 cohort 
60 mg kg−1 cohort  120 mg kg−1 cohort 
90 mg kg−1 cohort 
-AcH4
6 h 24 h 48 h Baseline
-Actin -Actin
-AcH3
-AcH4
-AcH3
-AcH4
-Actin
-AcH3
-AcH4
-Actin
-AcH3
Baseline 6 h 24 h 48 h Baseline 6 h 24 h 48 h
6 h 24 h 48 h Baseline MW
MW
MW
MW
20.5
20.5
20.5
20.5
14.9
14.9
14.9
14.9
14.9 14.9
14.9 14.9
8.4
8.4
8.4
8.4
49.5
37.4
49.5
37.4
49.5
37.4
49.5
37.4
63.8
49.5 -HDAC2 -HDAC2 49.5
63.8
-HDAC2 63.8
49.5
-HDAC2 63.8
49.5
AC
D B
Figure 2 Western blot analyses of peripheral blood lymphocytes from patients treated with VPA at different dose levels (A) 30, (B) 60, (C) 90, and (D)
120mgkg
 1 with antibodies directed against acetylated histones H3, H4, and HDAC-2. As a loading control for the histone protein, parallel gels were run
and stained for b-actin. Analysis was performed at baseline after 6, 24, and 48h. In all dose levels, an increase of histone hyperacetlyation and downregulation
of HDAC-2 were observed under VPA treatment. Molecular weights (MW) markers are given in kDa.
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sstudy, in addition, aimed to investigate whether intravenous VPA
induces hyperacetylation in vivo, as assessed in patients’ PBL. To
our knowledge, this study represents the first report of a clinical
trial with VPA as a HDAC inhibitor in patients with solid tumours.
The treatment was well tolerated in patients treated with VPA 30
or 60mgkg
 1day
 1. These patients had median VPA concentra-
tions ranging between 50 and 120mgl
 1, which were slightly
higher than those observed in patients receiving VPA during
anti-epileptic therapy (Loscher, 1999). On the other hand, severe
neurological side effects including disorientation, confusion, and
somnolence dominated the toxicity profile and were dose limiting
in most of the patients who received VPA at 90 or
120mgkg
 1day
 1. In these patients, median and maximum VPA
serum concentrations were 4120 and 200mgl
 1, respectively.
After an additional dose level at 75mgkg
 1day
 1 was also found
toxic (DLT in two out of five patients), the MTD of infusional VPA
was defined as 60mgkg
 1day
 1 for 5 consecutive days. This dose
is consistent with the results of a phase 1/2 study reported by
Garcia-Manero et al (2006) in patients with advanced leukaemia
receiving the combination of a fixed dose of 5-aza-20-deoxycytidine
and escalating doses of VPA for 10 days, where a daily dose of
50mgkg
 1 of VPA was found to be safe.
The availability of an oral formulation of VPA represents an
additional advantage of VPA. We, however, preferred the
intravenous over the oral use of VPA in the study because we
expected that a proportion of the study patients may have
gastrointestinal disturbances (due to the very advanced stages of
disease) which may affect the uptake of VPA.
In vitro experiments by Yang and colleagues (Yang et al, 2005)
demonstrated that high doses of VPA were needed to show
hyperacetylation and antitumour effects in tumour cell lines. The
amount of hyperacetylation was enhanced with increasing
concentrations of VPA up to 10mM (Yang et al, 2005). In
consideration of these data, we chose an intermittent schedule of
VPA in an attempt to be able to administer higher doses of VPA, as
it would have been possible using the continuous dosing. The
results, however, showed that we could not markedly increase the
dose of VPA safely over that usually used in the long-term
treatment.
The use of VPA in our study was associated with an increase of
acetylated histones and a decrease of HDAC2 protein levels as
assessed by western blot analysis and flow cytometry in peripheral
blood lymphocytes of patients in all dose levels. This is important
because it suggests that we could achieve detectable biological
activity using the lower doses of VPA, which were found tolerable
in the study. Notably, we did not evaluate the histone acetylation
status of the tumours. In a recent study, however, the accumula-
tion of acetylated histones in peripheral blood mononuclear
cells after the administration of the HDAC inhibitor SAHA
correlated well to the accumulation of acetylated histones in
patients’ tumours as assessed by immunohistochemistry (Kelly
et al, 2003).
Efficacy was a secondary end point of the trial. No radiological
responses were observed. One patient with metastatic non-small-
cell lung cancer and one additional patient with metastatic
colorectal cancer had a stable disease, lasting 3 and 5 months,
respectively. Both patients had documented rapid disease progres-
sion under their prior cytotoxic therapy, as was documented by
subsequent CT scans. The stable disease achieved in these patients
may, therefore, be related to VPA. Overall, the efficacy results of
our study are, in fact, very difficult to interpret due to several
aspects, including the small size and heterogeneity of the study
population. Objective responses to HDAC inhibitors have been
observed using SAHA in patients with lymphoma and bladder
cancer (Kelly et al, 2003) or VPA in combination with all-trans
retinoic acid in patients with acute leukaemia (Bug et al, 2005;
Kuendgen et al, 2006). The activity of VPA in patients with solid
tumours may be improved by patient selection based on biological
parameters (e.g. HDAC2 overexpression) or by the combination of
VPA with drugs that may act synergistic with HDAC inhibitors.
Additive effects of VPA and mitomycin C could be demonstrated
in adenocarcinoma cell lines and fresh tumour cells from patients
with colon cancer in vitro by our group (Friedmann et al, 2006).
Future studies are needed to investigate these issues.
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